Bayer Shuffles Atara’s CAR-Ts Out Of Its Cell Therapy Deck

Biotech’s Fortunes Riding On Other Assets

 
• By Andrew McConaghie
  
Bayer, Wuppertal
Bayer will now focus on its in-house cell and gene therapy pipeline via subsidiaries AskBio and BlueRock Therapeutics. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip